[AVK III: Below the knee].

Erwin Blessing

Abstract readEnglish AbstractReview

In one paragraph

Review in Innere Medizin (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Erwin BlessingKlinik für Gefäßmedizin, Universitäres Herz- und Gefäßzentrum, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland. e.blessing@uke.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There has been great progress in the field of endovascular therapy in recent years, particularly in the femoropopliteal vascular segment. Of particular importance here is lesion preparation, which has led to a significant reduction in restenosis and thus revascularisation rates. The use of mostly paclitaxel-based drug-coated balloons or stents has shown clear advantages over conventional balloon dilatation (POBA). This article will present and describe the various balloon and stent systems that can be used in endovascular therapy below the knee.

Indexed as

Angioplasty, BalloonEndovascular ProceduresLegPeripheral Arterial DiseaseDrug-Eluting StentsHumansPaclitaxelPopliteal ArteryStentsPaclitaxelBioresorbable vascular scaffoldsDrug-eluting balloonsInterventions below-the-knee“No option” patientsScoring balloons

Identifiers

PMID40019531

DOI10.1007/s00108-025-01871-y

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.